Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1672 • ACR Convergence 2024
The Evaluation of SLE Outcome Measures in Telemedicine
Maya Souvignier¹, Cynthia Aranow², Anca Askanase¹, Mimi Kim³, Diane Kamen⁴, Cristina Arriens⁵, Leila Khalili¹, Wei Tang⁶, Maria Dall'Era⁷ and Meggan Mackay⁸, ¹Columbia University Medical Center, New York, NY, ²Feinstein Institutes for Medical Research, New York, NY, ³Albert Einstein College of Medicine, New York, NY, ⁴Medical University of South Carolina, Charleston, SC, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Westchester Medical Center, Valhalla, ⁷UCSF, Corte Madera, CA, ⁸Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: Telemedicine (TM) has been integral to rheumatology care since the Covid-19 pandemic; evidence suggests high acceptance, satisfaction, and feasibility. However, due to the complexity…
Abstract Number: 1754 • ACR Convergence 2024
Comparing the Molecular Landscape of the CAR-T Cell and Rituximab Mediated Remission in Systemic Lupus Erythematosus
Panagiotis Garantziotis¹, Ioannis Parodis², George Bertsias³, Dimitrios Boumpas⁴ and Georg Schett⁵, ¹Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany, Erlangen, Germany, ²Karolinska Institutet, Karolinska University Hospital; Örebro University, Solna, Sweden, ³Laboratory of Rheumatology, Autoimmunity and Inflammation. University Hospital, Rheumatology, Clinical Immunology, Heraklion, Greece, ⁴4th Department of Internal Medicine, "Attikon" University Hospital, Athens, Greece, Athens, Greece, ⁵Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Background/Purpose: Despite the negative clinical trials, B-cell depletion by antibodies has been used off-label to treat refractory Systemic Lupus Erythematosus (SLE). Emerging evidence shows that CD19…
Abstract Number: 1794 • ACR Convergence 2024
Biobehavioral Basis and Outcomes of Cognitive Dysfunction in Childhood Systemic Lupus Erythematosus
Hanne van der Heijden¹, Andrea Knight², Itamar Ronen³, Gabrielle Alonzi⁴, Kyle McBrearty⁴, Aditi Deokar⁴, Joseph Gonzalez-Heydrich⁴, Joyce Chang⁴ and Jaymin Upadhyay⁵, ¹Boston Children's Hospital Harvard Medical School, Boston, MA, ²Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ³Brighton and Sussex Medical School, University of Sussex, Brighton, UK, Brighton, United Kingdom, ⁴Boston Children's Hospital, Boston, MA, ⁵Boston Children's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Cognitive dysfunction (CD) in childhood-onset SLE (cSLE) is undertreated yet profoundly impacts lifelong health-related quality of life. Investigating CD in cSLE is crucial, given…
Abstract Number: 1842 • ACR Convergence 2024
Development of Next Generation CAR T Cell Therapy for the Off-the-shelf Treatment of Autoimmune Diseases Without Conditioning Chemotherapy
John Goulding¹, John Reiser², Alison O'Connor¹, Bryan Hancock¹, Jonatan Tuncel¹, Brian Groff¹, Rina Mbofung¹, Daniel Morales-Mantilla¹, Allan Williams¹, Dan Lu¹, Bi-Huei Yang¹, Eigen Peralta¹, Alma Gutierrez¹, Miguel Meza¹, Betsy Rezner¹, Amanda Sims¹, Alec Witty¹, Yijia Pan¹, Mark Jelcic¹, Shohreh Sikaroodi¹, Matthew Denholtz¹, Tom Lee¹, Anil Bagri¹, Lilly Wong¹, Jode Goodridge¹ and Bahram Valamehr¹, ¹Fate Therapeutics Inc., San Diego, CA, ²Fate Therapeutics Inc, San Diego, CA
Background/Purpose: Developed initially as a novel strategy to treat B cell malignancies, chimeric antigen receptor (CAR) T cells have now been used to treat multiple…
Abstract Number: 2120 • ACR Convergence 2024
EvaluationofBone Mineral Densityand Trabecular Bone Score in JuvenileSystemicLupusErythematosusPatientsUsing Dual-Energy X-rayAbsorptiometry
BEATRIZ ROSA¹, Melissa Fraga¹, Erica Barbosa¹, Jade Dib Fernandez², Marcelo Pinheiro³ and Maria Teresa Terreri⁴, ¹Universidade Federal de São Paulo, São Paulo, SP, Brazil, ²UNIFESP-EPM, São Paulo, SP, Brazil, ³UNIFESP/ EPM, São Paulo, SP, Brazil, ⁴UNIFESP, São Paulo, SP, Brazil
Background/Purpose: Juvenile Systemic Lupus Erythematosus (jSLE) is a multisystem inflammatory disease associated with bone mass loss. This loss can be evaluated by using the bone…
Abstract Number: 2379 • ACR Convergence 2024
Causal Proteomics-Assisted Machine Learning Model Enhances Flare Risk Prediction in Systemic Lupus Erythematosus
Liying Chen¹, Ou Deng², Ruichen Cong², Dingqi Lu³, Ting Fang¹, Mei Chen¹, Runrun Zhang⁴ and Xinchang Wang³, ¹Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China (People's Republic), ²Graduate School of Human Sciences, Waseda University, Mikajima, Japan, ³Department of Rheumatology, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China (People's Republic), ⁴The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China (People's Republic)
Background/Purpose: Objectives: Systemic lupus erythematosus (SLE) is an autoimmune disease marked by unpredictable flares. However, no flare risk prediction model has been developed for Asian…
Abstract Number: 2397 • ACR Convergence 2024
Increase of IL10 and IFNa2 Are Associated to Clinical Activity in Systemic Lupus Erythematous Patients
Elena Grau García¹, Marta De la Rubia Navarro², Samuel Leal Rodriguez¹, José Ivorra-Cortés³, Carmen Riesco Barcena⁴, Anderson Huaylla Quispe⁴, Laura Mas Sánchez⁵, Pablo Muñoz Martínez⁶, Daniel Ramos Castro⁴, Alba Torrat noves⁷, Iago Alcantara Alvarez², Belén Villanueva Mañés², Miguel Simeo Vinaixa², Andrés Pérez Hurtado⁴ and Jose A Román-Ivorra⁸, ¹HUP La Fe, Valencia, Spain, ²Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ³Hospital Universitario La Fe, PALMA DE MALLORCA, Spain, ⁴Rheumatology Department. HUP La Fe, Valencia, Spain, ⁵Resident at Hospital Universitari i Politecnic La Fe, Valéncia, Spain, ⁶Hospital Universitario y Politècnico La Fe, Sagunto, Spain, ⁷Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Comunidad Valenciana, Spain, ⁸Hospital Universitari i Politècnic la Fe, Valencia, Comunidad Valenciana, Spain
Background/Purpose: Systemic lupus erythematous (SLE) is an autoimmune disease characterized by deregulation of cytokine production. Interferon (IFN) is a proinflamatory cytokine considered as a key…
Abstract Number: 2415 • ACR Convergence 2024
Characterizing the Population with Suspected Lupus Nephritis in Care of a Community Rheumatology Network
Nehad Soloman¹, Jawad Bilal², Romy Cabacungan³, Scott Milligan⁴, Andrew Sharobeem⁵, John Tesser⁶ and Henry Leher⁷, ¹Arizona Arthritis & Rheumatology Associates, P.C., Glendale, AZ, ²University of Arizona, Tucson, AZ, ³Arizona Arthritis & Rheumatology Associates, P.C., Tucson, AZ, ⁴Trio Health, Louisville, CO, ⁵AARA, Peoria, AZ, ⁶Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ⁷Aurinia Pharma, Stowe, VT
Background/Purpose: Lupus nephritis (LN) has been estimated to develop in up to 40% of all patients with systemic lupus erythematosus (SLE), with higher rates in…
Abstract Number: 2432 • ACR Convergence 2024
In Vitro and In Vivo Evidence of the Steroid-Sparing Potential of Afimetoran, an Equipotent Toll-Like Receptor 7/8 Dual Antagonist
Shailesh Dudhgaonkar¹, Siva Subramani², Puneet Chopra², Anjuman Rudra², Sourabha Palachandra², Nikita Sanjay Bhatt², Veeresh Pabbala², Sabariya Selvam², Mobeen Shaik², Amit Anand², Benjamin King³, Kristina Chadwick³, Alaric Dyckman³, Qihong Zhao³, Frédéric Baribaud³, Ramya Janardhana⁴ and Vineeta Shobha⁵, ¹Bristol Myers Squibb, Bangalore, India, ²Biocon BMS Research Center, Syngene International Ltd, Bangalore, India, ³Bristol Myers Squibb, Princeton, NJ, ⁴St. John’s Medical College, Bengaluru , India, Bangalore, India, ⁵St. John’s Hospital, Bangalore, India
Background/Purpose: SLE is a highly heterogeneous chronic autoimmune disease, with glucocorticoid therapy as the standard of care. SLE control requires high steroid doses; long-term use…
Abstract Number: 2577 • ACR Convergence 2024
Efficacy and Safety of ABBV-599 (Elsubrutinib and Upadacitinib Combination) and Upadacitinib Monotherapy for the Treatment of Systemic Lupus Erythematosus: Results Through 104 Weeks in a Long-Term Extension Study
Joan Merrill¹, Amit Saxena², Martin Aringer³, Yoshiya Tanaka⁴, Xiaofeng Zeng⁵, Peter Wung⁶, Ling Cheng⁶, Thao Doan⁶, Shelly Kafka⁶, David DCruz⁷ and Kristin D'Silva⁶, ¹Oklahoma Medical Research Foundation, Oklahoma City 73104, OK, ²NYU Grossman School of Medicine, New York, NY, ³University Medical Center and Faculty of Medicine, TU Dresden, Dresden, Germany, ⁴Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ⁵Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China, ⁶AbbVie Inc., North Chicago, IL, ⁷The Louise Coote Lupus Unit, Guy's and St Thomas' Hospitals NHS Foundation Trust, London, United Kingdom
Background/Purpose: ABBV-599 (a combination of a selective Bruton’s tyrosine kinase inhibitor, elsubrutinib [ELS], and a selective Janus kinase inhibitor, upadacitinib [UPA]) targets a spectrum of…
Abstract Number: 2662 • ACR Convergence 2024
In Vivo Generation of B Cell Depleting CAR T Cell Therapies for Treatment of Autoimmune Diseases
Laurie Beitz¹, Maura Parker¹, Justin Ulrich-Lewis¹, Kristen Mittelsteadt¹, Rebecca Gottschalk¹, Chris Nicolai¹, Jim Qin¹, Andrew Scharenberg¹, Ryan Larson¹, Byoung Ryu¹, Eric Cavanaugh², Weiliang Tang¹, Seungjin Shin¹, Kelsey Lynch¹ and Hans-Peter Kiem², ¹Umoja Biopharma, Seattle, WA, ²Fred Hutch Cancer Research Center, Seattle, WA
Background/Purpose: CAR T cell therapy promises to revolutionize the treatment of hematologic malignancies, and more recently has generated early data that it may afford long…
Abstract Number: 0011 • ACR Convergence 2024
Preclinical Manufacturability and Activity of KYV-102 from Patients with Systemic Lupus Erythematosus Using Ingenui-T: A Rapid, Autologous Chimeric Antigen Receptor T-Cell Manufacturing Solution Utilizing Whole Blood
Brandon Kwong¹, Daniel Anaya¹, Soo Park², Sunetra Biswas², Jeevitha Jeevan², Jesus Banuelos², Madison Strobach², Nicole Khoshnoodi¹, Timothy Klasson¹, Santiago Foos-Russ¹, Jennifer Zeng¹, Candice Gibson³, Jazmin Bravo², Simone Sandoval¹, Shouvonik Sengupta¹, Shairaz Shah¹, Tom Van Blarcom² and Karen Walker², ¹Kyverna Therapeutics, Inc., Emeryville, CA, ²Kyverna Therapeutics, Inc., Emeryville, ³Kyverna Therapeutics, Inc., Emerybille
Background/Purpose: Apheresis in conventional chimeric antigen receptor (CAR) T-cell therapy can be burdensome, and conventional manufacturing cultures apheresis-derived cells for 7-14 days, leading to a…
Abstract Number: 0109 • ACR Convergence 2024
Natural History and Clinical Implications of Lupus Autoantibodies in Primary Antiphospholipid Antibody Positive Patients: Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Rohan Willis¹, Anne Tebo², Leslie Skeith³, Nina Kello⁴, H Michael Belmont⁵, Paul Fortin⁶, Guilherme Ramires de Jesús⁷, David Branch⁸, Michelle Petri⁹, Jason Knight¹⁰, Reyhan Kose Cobanoglu¹¹, Maria Laura Bertolaccini¹², Hannah Cohen¹³, Robert Roubey¹⁴, Doruk Erkan¹⁵ and Danieli Andrade¹⁶, and on behalf of APS ACTION, ¹University of Texas Medical Branch, Galveston, TX, ²Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, ³University of Calgary, Calgary, ON, Canada, ⁴Northwell Health, Brooklyn, NY, ⁵NYU School of Medicine, New York, NY, ⁶Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ⁷Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, ⁸University of Utah and Intermountain Healthcare, Salt Lake City, UT, ⁹Johns Hopkins University School of Medicine, Timonium, MD, ¹⁰University of Michigan, Ann Arbor, MI, ¹¹Aydin Adnan Menderes University School of Medicine, Hospital for Special Surgery, NY, USA, Aydin, Turkey, ¹²King's College London, London, United Kingdom, ¹³University College London Hospitals NHS Foundation Trust, London, United Kingdom, ¹⁴Division of Rheumatology, Allergy, and Immunology, University of North Carolina, Chapel Hill, NC, ¹⁵Hospital for Special Surgery, New York, NY, ¹⁶University of São Paulo, São Paulo, SP, Brazil
Background/Purpose: Antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) are characterized by heterogenous clinical presentations, driven by autoantibodies; patients with SLE develop APS more often…
Abstract Number: 0181 • ACR Convergence 2024
Integrated Multidisciplinary Lupus Social Work Program to Manage Social Determinants of Health in SLE and Lupus Nephritis – Preliminary Results
Kimberly DeQuattro¹, Stephanie DeVaughn², Andrew Kanoff³ and Abdallah Geara¹, ¹University of Pennsylvania, Philadelphia, PA, ²Uniersity of Pennsylvania, Pennsylvania, ³University of Pennsylvania, Philadelphia, PA, Philadelphia, PA
Background/Purpose: Minoritized individuals with systemic lupus erythematosus (SLE) experience social determinants of health (SDOH) challenges that affect access to care and increase the risk for…
Abstract Number: 0212 • ACR Convergence 2024
Costs of Hospitalization in Patients with SLE: An Analysis of the National Inpatient Sample
Brandon Blau¹, Kelsey Gripp¹, Catherine MacLean² and Bella Mehta², ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with significant health care utilization, medical costs, and increased risk of hospitalization. We aimed to characterize the reasons…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].